MY139957A - Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-1-(pyridin-2-ylmethyl)piperidin-4-yl-1h-indol-3-yl-1h-pyrrole mono-hydrochloride - Google Patents

Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-1-(pyridin-2-ylmethyl)piperidin-4-yl-1h-indol-3-yl-1h-pyrrole mono-hydrochloride

Info

Publication number
MY139957A
MY139957A MYPI20022777A MY139957A MY 139957 A MY139957 A MY 139957A MY PI20022777 A MYPI20022777 A MY PI20022777A MY 139957 A MY139957 A MY 139957A
Authority
MY
Malaysia
Prior art keywords
indol
piperidin
ylmethyl
dione
crystalline
Prior art date
Application number
Inventor
Bush Julie Kay
Faul Margaret Mary
Reutzel-Edens Susan Marie
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority to MYPI20022777 priority Critical patent/MY139957A/en
Priority to MYPI20032577 priority patent/MY138934A/en
Publication of MY139957A publication Critical patent/MY139957A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

THE PRESENT INVENTION RELATES TO CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-[1-(PYRIDINE-2-YLMETHYL)PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-PYRROLE MONO-HYDROCHLORIDE SALT, A PHARMACEUTICAL FORMULATION CONTAINING SAID SALT AND TO METHODS FOR TREATING CANCER AND FOR INHIBITING TUMOR GROWTH USING SAID SALT.
MYPI20022777 2002-07-23 2002-07-23 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-1-(pyridin-2-ylmethyl)piperidin-4-yl-1h-indol-3-yl-1h-pyrrole mono-hydrochloride MY139957A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MYPI20022777 MY139957A (en) 2002-07-23 2002-07-23 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-1-(pyridin-2-ylmethyl)piperidin-4-yl-1h-indol-3-yl-1h-pyrrole mono-hydrochloride
MYPI20032577 MY138934A (en) 2002-07-23 2003-07-09 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20022777 MY139957A (en) 2002-07-23 2002-07-23 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-1-(pyridin-2-ylmethyl)piperidin-4-yl-1h-indol-3-yl-1h-pyrrole mono-hydrochloride

Publications (1)

Publication Number Publication Date
MY139957A true MY139957A (en) 2009-11-30

Family

ID=45699544

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI20022777 MY139957A (en) 2002-07-23 2002-07-23 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-1-(pyridin-2-ylmethyl)piperidin-4-yl-1h-indol-3-yl-1h-pyrrole mono-hydrochloride
MYPI20032577 MY138934A (en) 2002-07-23 2003-07-09 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI20032577 MY138934A (en) 2002-07-23 2003-07-09 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Country Status (1)

Country Link
MY (2) MY139957A (en)

Also Published As

Publication number Publication date
MY138934A (en) 2009-08-28

Similar Documents

Publication Publication Date Title
IL172924A0 (en) 3.5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
TW200621751A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
CA2399358A1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
ZA200508830B (en) Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
MXPA02005844A (en) Inhibitors of protein kinases.
MXPA03007621A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists.
PL406680A1 (en) Tyrosine kinase inhibitors
ATE381557T1 (en) RHO KINASE INHIBITORS
UA96126C2 (en) Compound for inhibition of rhokinase activity, pharmaceutical composition comprising such a compound and method of inhibiting the activity of a rhokinase
TR200200205T2 (en) Treating chronic pain using MEK inhibitors
MY134783A (en) Rho-kinase inhibitors
HRP20050035B1 (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
BG106585A (en) Kinase inhibitors as therapeutic agents
MXPA04006271A (en) Indolinone derivatives useful as protein kinase inhibitors.
AP2002002596A0 (en) Piperazine and piperidine derivatives.
MXPA05009611A (en) SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS.
MXPA05009151A (en) Heterocyclic kinase inhibitors.
MXPA05013151A (en) 3-fluoro-piperidines as nmda/nr2b antagonists.
MXPA02000330A (en) Neurotrophic pyrrolidines and piperidines, and related compositions and methods.
AU2003300385A1 (en) Anticancer compounds
EA200501233A1 (en) 4-AMINOPYRIMIDIN-5-OH
WO2004058705A3 (en) Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor
MY139957A (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-1-(pyridin-2-ylmethyl)piperidin-4-yl-1h-indol-3-yl-1h-pyrrole mono-hydrochloride
YU46302A (en) Substituted pyrroles